We dont yet know: So while the idea of low-dose Wegovy for energy, appetite control, or menopause support is interesting, its not backed by strong science (at least not yet)
At consultation your surgeon will tell you honestly what your face actually needs
It mimics how the gut hormone
Novo Nordisk has published phase 3 data showing that a dual therapy comprising cagrilintide and semaglutide (the GLP-1 agonist in Wegovy), coupled with lifestyle interventions, achieved an average of 13.7% weight loss in patients with type 2 diabetes, who are also overweight or obese, over a period of 68 weeks 8
a possible explanation to conflicting results of studies of ADHD in females
Diagnostic tests included are MRIs, CT scans, EKGs, and X-rays